Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

The current phase 2, double cohort clinical trial was designed to determine the effectiveness of Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab with/without involved lesions irradiation as 3rd- or later-line therapy for advanced MSS/pMMR colorectal cancer.

Trial Details

NCT ID

NCT06764680

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Trifluorouracil tepidopyrimidine
Bevacizumab
Sindilizumab
IMRT

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

patients with advanced colorectal adenocarcinoma of MSS/pMMR confirmed by histologic or cytologic diagnosis;
aged 18 years and older;
have a quality of life score of 0-1 according to the Eastern Cooperative Oncology Group (ECOG);
can take oral medications;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →